UnknownPhase 3NCT03252353

Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly

Studying Acromegaly

Last synced from ClinicalTrials.gov May 14, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Chiasma, Inc.
Principal Investigator: Susan L Samson, MD PhD
Pituitary Center at Baylor St. Luke's Medical
Intervention: octreotide capsules(drug)
Enrollment: 56 enrolled
Eligibility: 18 years · All sexes
Timeline: 2017 – 2022

Study locations (30)

Keck Medical Center of University of Southern California, Los Angeles, California, United States
Cedars-Sinai Medical Center, Los Angeles, California, United States
UCLA Medical Center, Los Angeles, California, United States
Stanford University School of Medicine, Palo Alto, California, United States
University of Colorado, Aurora, Colorado, United States
The Emory Clinic, Atlanta, Georgia, United States
John H. Stroger Jr. Hospital of Cook County, Chicago, Illinois, United States
Johns Hopkins University Clinical Trials Unit, Baltimore, Maryland, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Washington University School of Medicine, St Louis, Missouri, United States
Columbia University Medical Center, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Cleveland Clinic, Cleveland, Ohio, United States
Ohio State University, Columbus, Ohio, United States
Oregon Health and Science University, Portland, Oregon, United States
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03252353 on ClinicalTrials.gov

Other trials for Acromegaly

Additional recruiting or active studies for the same condition.

See all trials for Acromegaly →

← Back to all trials